Neutral
North Dakota State Investment Board bought a new position in Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 4th quarter, HoldingsChannel reports. Th...
Neutral
Moderna's mRNA flu vaccine, MFLUSIVA, will undergo scrutiny from the FDA's Vaccines and Related Biological Products Advisory Committee next month, aft...
Neutral
Moderna's stock saw a 20% surge due to emerging hantavirus cases, reminding investors of its pandemic defense capabilities, despite experts suggesting...
Bullish
Moderna Inc. (US60770K1034) shares are closely watched by U.S. investors due to developments in its mRNA pipeline, vaccine demand, and regulatory mile...
Neutral
Moderna shares experienced a slip as the company navigates its transition from pandemic-driven COVID-19 vaccine sales to a broader portfolio of mRNA v...
Neutral
Virginia Retirement Systems increased its stake in Moderna by 64.3% in Q4, acquiring 23,550 additional shares, bringing its total holdings to $1.77 mi...
Bullish
Moderna Inc is transitioning its business model from a pandemic-driven revenue surge to a more diversified, pipeline-driven approach, focusing on mRNA...
Moderna, Inc. has filed a Rule 144 notice indicating a proposed sale of 53,336 shares of Common Stock through Fidelity Brokerage Services on May 15, 2...
Neutral
Moderna (US60770K1034) is transitioning beyond COVID-19 vaccines, with its stock remaining volatile as focus shifts to its broader mRNA pipeline, incl...
Bullish
S&P 500 futures remained steady in premarket trading. Everpure Inc. and Moderna Inc. were notable movers, with Everpure up 11.2% and Moderna up 8.3% a...
Neutral
Mitsubishi UFJ Asset Management Co. Ltd. decreased its stake in Moderna by 5.8% in Q4 2026, selling 24,187 shares and retaining 390,028 shares valued ...
Bullish
Moderna's stock surged by 8% in premarket trading after a U.S. citizen on the MV Hondius cruise ship tested positive for the Andes strain of hantaviru...
Bullish
Moderna's stock rose after the company announced positive Phase 1 data for its mRNA hantavirus vaccine, which was shown to be well-tolerated and gener...
Neutral
Novavax (NVAX) shares are experiencing a breakout week after the company reported strong Q1 results, surpassing analyst estimates with revenue of $139...
Neutral
Sigma Planning Corp has made a new investment of $907,000 in Moderna, Inc., purchasing 30,761 shares in the fourth quarter. This move is part of broad...
Neutral
Moderna director Hussain Abbas sold 5,682 shares of the company's common stock for $264,951 on May 1, 2026. This sale, executed via a Rule 10b5-1 trad...
Neutral
The Zacks Analyst Blog features Moderna, Merck, and Vertex Pharmaceuticals, highlighting Moderna's Q1 2026 earnings. Moderna reported a lower-than-exp...
Neutral
Brookline Capital Markets has slightly lowered its FY2029 EPS forecast for Moderna to $11.83, while projecting $19.45 for FY2030, indicating a short-t...
Moderna (MRNA) stock experienced a five-day losing streak, resulting in an 18% decline. The article mentions financial market data sources and disclai...
Neutral
Moderna, Inc. (NASDAQ:MRNA) has received an average "Reduce" rating from brokerages, with an average 12-month price target of $33.87. While regulatory...